v3.26.1
Interim Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Income Statement [Abstract]        
Revenues $ 293 $ 370 $ 646 $ 899
Costs and Expenses:        
Traffic-acquisition and related costs 134 50 266 184
Research and development 185 20 185 36
Selling and marketing 26 30 51 50
General and administrative 1,015 558 1,515 755
Depreciation and amortization 228 235 452 408
Other expenses, net 100 500 122 544
Operating loss (1,395) (1,023) (1,945) (1,078)
Gain from deconsolidation of CliniQuantum 3,831 3,831
Financial expenses, net 113 7,661 184 10,528
Income (loss) from continuing operations, before taxes 2,323 (8,684) 1,702 (11,606)
Tax benefit (94) (67) (110) (25)
Net income (loss) from continuing operations 2,417 (8,617) 1,812 (11,581)
Net loss from discontinued operations (3,801) (4,681)
Net income (loss) 2,417 (12,418) 1,812 (16,262)
Less: net loss attributable to non-controlling interests (68) (760) (68) (936)
Net income (loss) attributable to shareholders of Quantum X Labs Inc. 2,485 (11,658) 1,880 (15,326)
Net income (loss) from continuing operations attributable to:        
Shareholders of Quantum X Labs Inc. 2,485 (8,617) 1,880 (11,581)
Non-controlling interests (68) (68)
Net loss from continuing operations 2,417 (8,617) 1,812 (11,581)
Net loss from discontinued operations attributable to:        
Shareholders of Quantum X Labs Inc. (3,041) (3,745)
Non-controlling interests (760) (936)
Net loss from discontinued operations $ (3,801) $ (4,681)
Net income (loss) per share from continuing operations attributed to shareholders:        
Basic $ 0.17 $ (1.19) $ 0.15 $ (1.83)
Diluted 0.12 (1.19) 0.10 (1.83)
Net loss per share from discontinued operations - Basic attributed to shareholders (0.42) (0.59)
Net loss per share from discontinued operations - Diluted attributed to shareholders (0.42) (0.59)
Total net income (loss) per share attributed to shareholders:        
Basic 0.17 (1.61) 0.15 (2.42)
Diluted $ 0.12 $ (1.61) $ 0.10 $ (2.42)
Weighted average number of shares (*):        
Basic [1] 14,292,085 7,235,599 12,903,662 6,330,104
Diluted [1] 20,074,625 7,235,599 19,043,862 6,330,104
[1] Share and per share data in these financial statements for periods preceding the Reverse Stock Split have been retrospectively adjusted to reflect a number of shares that is equivalent to the number of shares of the Company post the Reverse Stock Split (see note 10.G).